Lessons Learned from REACH-3 Clinical Trial
Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm compared to 60% in the best-available therapy arm.
EP: 1.Patient Case: Pathology of Graft Versus Host Disease
EP: 2.Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease
EP: 3.Lessons Learned from REACH-3 Clinical Trial
EP: 4.Updates on the iNTEGRATE and ROCKstar Trials
EP: 5.Second-Line Medications and Toxicities in GVHD
EP: 6.Quality of Life + Clinical Monitoring Outside the Transplant Center
EP: 7.AGAVE-201 Data on Refractory cGvHD
EP: 8.The Future of Graft Versus Host Disease
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
